Advancements in Biotech: Breakthroughs and Prevention Strategies for Alzheimer's Disease
The hunt for Alzheimer's treatments has seen significant breakthroughs this year, with the approval of drugs like Leqembi and donanemab that target the buildup of toxic plaque in the brain. While these drugs slow cognitive decline, they do not offer a complete cure. Biotech companies are exploring ways to improve the safety and delivery of these treatments, as well as looking beyond the removal of beta amyloid to other potential drug targets. The successes in Alzheimer's treatment have created excitement in the biotech industry, with new players expected to emerge in a market projected to be worth $13.7 billion by 2030. Despite the challenges, there is hope that continued research and innovation will lead to better and more effective ways of tackling this devastating disease.
